Natixis Legend Biotech Corp Transaction History

Natixis

$18 Billion
Q1 2025

A detailed history of Natixis transactions in Legend Biotech Corp stock. As of the latest transaction made, Natixis holds 785 shares of LEGN stock, worth $28,134. This represents 0.0% of its overall portfolio holdings.

Number of Shares

785

Previous 849 7.54%

Holding current value

$28,134

Previous $27,000 3.7%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	SELL	$31.43 - $39.7 $2,011 - $2,540	-64 Reduced 7.54%	785 $26,000
Q4 2024 Feb 13, 2025	SELL	$32.49 - $50.28 $5,263 - $8,145	-162 Reduced 16.02%	849 $27,000
Q3 2024 Nov 13, 2024	SELL	$43.55 - $59.88 $2,351 - $3,233	-54 Reduced 5.07%	1,011 $49,000
Q2 2024 Aug 13, 2024	SELL	$39.5 - $57.22 $13,390 - $19,397	-339 Reduced 24.15%	1,065 $47,000
Q1 2024 May 13, 2024	SELL	$55.06 - $69.99 $34,027 - $43,253	-618 Reduced 30.56%	1,404 $78,000
Q4 2023 Feb 13, 2024	SELL	$57.25 - $69.74 $6,068 - $7,392	-106 Reduced 4.98%	2,022 $121,000
Q3 2023 Nov 14, 2023	SELL	$63.16 - $76.5 $62,717 - $75,964	-993 Reduced 31.82%	2,128 $142,000
Q2 2023 Aug 11, 2023	SELL	$46.28 - $75.01 $32,488 - $52,657	-702 Reduced 18.36%	3,121 $215,000
Q1 2023 May 12, 2023	SELL	$43.42 - $57.37 $10,290 - $13,596	-237 Reduced 5.84%	3,823 $184,000
Q4 2022 Feb 24, 2023	BUY	$38.8 - $55.46 $157,528 - $225,167	4,060 New	4,060 $202,000
Q2 2022 Aug 12, 2022	SELL	$33.54 - $55.0 $267,447 - $438,570	-7,974 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$31.02 - $48.18 $3,350 - $5,203	-108 Reduced 1.34%	7,974 $290,000
Q4 2021 Feb 14, 2022	BUY	$41.14 - $56.98 $28,222 - $39,088	686 Added 9.28%	8,082 $377,000
Q3 2021 Nov 12, 2021	BUY	$35.31 - $50.56 $261,152 - $373,941	7,396 New	7,396 $372,000

Others Institutions Holding LEGN

# of Institutions

229

Shares Held

74.4M

Call Options Held

247K

Put Options Held

406K

View Full List

About Legend Biotech Corp

Ticker LEGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 167,403,008
Market Cap $6B
Description
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...

More about LEGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

News

Stay updated on Natixis with notifications on news.

Account